RESEARCH
"Research is to see what everybody else has seen, and to think what nobody else has thought."
- Albert Szent-Gyorgyi
BVE Insights Series:
The Role of Government and Future of Healthcare
Private Event | Manhattan Beach, California | November 17, 2022
The Bonaventure Equity team was in Manhattan Beach on November 17th hosting the Psychedelic Policy & Investment Summit West. Going beyond the headlines attendees participated in leading edge discussions with investors, policy makers, veteran's groups and researchers about how healthcare and patient care is being transformed.
Topics Discussed:
1.) The FDA and DEA's framework for approving psychedelic compounds and congress's potential review of the current laws.
2. ) Leading academic institutions clinical studies identifying potentially new uses for psychedelics.
3.) The veteran's community legitimate use cases validating the positive effects of using psychedelics to treat many conditions they confront.
BVE Insights Series:
Canna Pharma 2022 Recap
BVE's Venture Partner and lead IP expert, Mike McCormick recently attended the Canna Pharma 2022 conference in San Diego, California. Presenters at the conference covered various interesting topics including a new NIH funding program for cannabis companies, the development of new prodrugs, cannabinoid and terpene formulations, and drug delivery technologies, as well as industry-specific IP considerations. Many leading-edge companies and researchers presented and were in attendance, including representatives from Avicanna, Biopharmaceutical Research Company, GB Sciences, as well as Dr. Ethan Russo, former scientific advisor to GW pharmaceuticals and current CEO of CReDO Science.
Major takeaways from the conference:
We understand the state of the art,
Pursuing minor cannabinoids as drug candidates has merit,
Patentability is improved for cannabinoid derivatives and prodrugs over the natural
compounds, however, highly purified forms of the natural cannabinoids are also potentially
patentable. Moreover,THCV continues to show promise as a dietary cannabinoid, providing a THC like experience but without appetite stimulation, and;
Combination therapies comprising cannabinoids and terpenes as well as other compounds show promise for the treatment of various indications.
BVE Insights Series:
Research and Strategies for the Future of Healthcare
Private Dinner & Jazz Event | La Jolla, California | September 26, 2022
BVE continues the conversation on the convergence of life science innovation and the future of healthcare. This latest BVE Insights Series event featured leading academics and researchers, as well as change-makers in the life sciences space. While the presenting scientists delivered highly sophisticated insights on current and future research and development, the evening’s main takeaways were quite simple, psychedelic drugs are efficacious and are on the cusp of completely transforming healthcare.
Investor Survey: Psychedelics
BVE Bulletin | September 2022
Active investors and those planning to invest in the psychedelics space recently contributed to a brief BVE survey. The takeaway is that investors are savvy, believe the tempered enthusiasm surrounding psychedelics is warranted, and are keeping a keen eye on big pharma’s M&A activity.
BVE Bulletin Survey | September 2022
BVE Insights Series:
Research and Strategies for the Future of Healthcare
The Wine Cellar at Angus Barn | September 8, 2022
BVE convened a group of investors and life science experts to discuss powerful trends reshaping the healthcare industry. The collective effort of regulatory agencies, academic institutions, and pioneering life science entrepreneurs are unlocking treatments for debilitating physical and mental health conditions, and Pharma has taken notice.
BVE Insights:
Key Takeaways from Benzinga’s Psychedelics & Cannabis Capital Conference 2022
BVE was honored to serve as the Spotlight Feature for Benzinga's Inaugural Psychedelics Capital Conference. This report includes our key takeaways from the broader Psychedelics & Cannabis Capital Conference experience. Many thanks to Benzinga for having us and for executing a stellar three-day event.
Cannabis Life Sciences: An Informed Outlook
The Q1: 2022 Cannabis Life Sciences: An Informed Outlook report provides data, trends, and regulatory considerations that inform BVE’s Cannabis Life Sciences investment strategy.